Phathom Pharmaceuticals Reports Robust Q1 2026 Financial Results and Maintains Guidance

Key Highlights

• VOQUEZNA® Prescription Momentum: Over 1.35 million total prescriptions filled to date, with 268,000 filled in Q1 2026, representing a 115% increase from Q1 2025.
• Revenue Growth: Q1 2026 net revenues of \$58.3 million, a 104% year-over-year increase.
• Expense Discipline: Q1 operating expenses of \$61.8 million (non-GAAP: \$56.2 million), reflecting a >40% reduction in cash operating expenses year-over-year.
• Net Loss: GAAP net loss narrowed significantly to \$30.4 million (vs. \$94.3 million in Q1 2025). Non-GAAP adjusted net loss was \$14.7 million (vs. \$77.1 million in Q1 2025).
• Cash Position: Cash and cash equivalents of \$180.9 million as of March 31, 2026, bolstered by a \$122 million equity raise in January and partial debt repayment in February.
• Guidance Maintained: FY 2026 net revenues forecasted at \$320–\$345 million; operating profitability expected in Q3 and for full year 2026; cash flow positivity targeted for 2027.
• Pipeline Update: Phase 2 pHalcon-EoE-201 trial for eosinophilic esophagitis (EoE) enrolling ahead of schedule; topline results expected late Q4 2026 or early Q1 2027.
• Insurance Coverage: 63% of Q1 VOQUEZNA prescriptions covered by insurance, with covered prescriptions up 91% year-over-year.
• Operational Improvements: Sales force realignment completed in 2025, now fully deployed and trained for Q2 2026.

Detailed Financial Performance

Guidance & Outlook

• 2026 Net Revenue: \$320–\$345 million
• Gross-to-net Discount: 55–59%
• Gross Margin: ~80%
• Non-GAAP Operating Expenses: \$235–\$255 million (excluding stock-based compensation)
• Operating Profitability: Expected from Q3 2026 and for full year 2026
• Cash Flow Positive: Targeted for 2027
• Cash Sufficiency: Company believes cash on hand and anticipated cash flow will fund all obligations without need for further equity or debt raises.

Pipeline and Commercial Progress

• Phase 2 clinical trial for EoE is ahead of schedule, with topline data expected by early 2027, offering upside potential if results are positive.
• Sales force expansion and pivot to GI market taking effect, with new-to-brand prescription momentum among top GI prescribers (30% share vs. PPIs).
• VOQUEZNA’s insurance coverage continues to expand, reaching new all-time highs for covered prescriptions in April 2026.

Risks and Considerations for Investors

• Phathom’s forward-looking statements are subject to risks including commercialization success, competition, reimbursement/market access, clinical trial outcomes, regulatory developments, and operational execution.
• Potential for generic competition or competitive product launches could impact VOQUEZNA’s market share and revenue trajectory.
• Phathom is dependent on third parties for manufacturing and commercialization; any issues could negatively affect results.
• The company has significant liabilities and a stockholders’ deficit, but expects improved results and cash flow as revenues scale.
• Any deviation from guidance or adverse clinical outcomes could materially affect share price.

Conclusion

Phathom Pharmaceuticals delivered a strong Q1 2026, with robust revenue growth, sharply reduced operating expenses, and significant narrowing of net losses. The company’s cash position is strong following an equity raise and partial debt repayment, and management maintains its ambitious guidance for 2026 and expects operating profitability in Q3. The commercial momentum for VOQUEZNA, especially among GI specialists, and the progress in clinical trials position Phathom favorably. However, risks remain, including market competition, reimbursement challenges, and clinical trial outcomes. These results and updates are likely to be of high interest to shareholders and could drive share price movement.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All financial information is based on company-reported results and forward-looking statements, which are subject to change and risks as described in Phathom Pharmaceuticals’ filings with the SEC. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions.

View Phathom Pharmaceuticals, Inc. Historical chart here